

14th November, 2025

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

BSE Scrip Code: - 524500

NSE SYMBOL: - KILITCH

Sub: Disclosure under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Monitoring Agency Report for the quarter ended 30th September, 2025

Dear Sir,

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith the Monitoring Agency Report dated 14th November, 2025, issued by Infomerics Valuation and Rating Limited, Monitoring Agency, for the quarter ended 30th September, 2025.

This disclosure will also be hosted on the Company's website viz: www.kilitch.com

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876



**Monitoring Agency Report
for Kilitch Drugs (India) Limited
for the quarter ended September 30,
2025**

Monitoring Agency Report

November 14, 2025

To

Kilitch Drugs (India) Limited
C-301/2 MIDC, TTC Industrial Area, Pawane Village,
Thane, Maharashtra, India, 400705,

Dear Sir,

Monitoring Agency Report for the quarter ended September 30, 2025 - in relation to the Right issue of Kilitch Drugs (India) Limited (“The Company”)

We write in our capacity of Monitoring Agency for the Right issue of equity shares for the amount aggregating to Rs. 49.92 crore of the Company and refer to our duties cast under 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations).

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended September 30, 2025, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated 02 July 2025.

Request you to kindly take the same on records.

Thanking you,

For and on behalf of Infomerics Valuation and Rating Limited

GAURAV NAVEEN JAIN Digitally signed by GAURAV
NAVEEN JAIN
Date: 2025.11.14 20:22:10 +05'30'

Gaurav Jain

(Director - Ratings)

gaurav.jain@infomerics.com

Report of the Monitoring Agency

Name of the Issuer: Kilitch Drugs (India) Limited

For quarter ended: September 30, 2025

Name of the Monitoring Agency: Infomerics Valuation and Rating Limited

(a) Deviation from the objects: No Deviation

(b) Range of Deviation: Not Applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses.

We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer.

We further declare that this report provides true and fair view of the utilization of issue proceeds.

**GAURAV NAVEEN
JAIN**

Digitally signed by GAURAV
NAVEEN JAIN

Date: 2025.11.14 20:22:40 +05'30'

Signature:

Name of the Authorized Person/Signing Authority:

Gaurav Jain

Designation of Authorized person/Signing Authority:

Director - Ratings

Seal of the Monitoring Agency:

Date: November 14, 2025



1) Issuer Details:

Name of the issuer: Kilitch Drugs (India) Limited

Names of the promoters of the issuer: Mukund Mehta and Kilitch Company (Pharma) Limited

Industry/sector to which it belongs: The Company is presently engaged in pharmaceutical manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe with over three decades of experience.

2) Issue Details:

Issue Period: July 23, 2025, to August 21, 2025

Type of issue (public/rights): Rights Issue

Type of specified securities: Rights Equity shares

Grading: Not Applicable

Issue size (Rs in Crores): Rs. 49.92 crores (Note No. 1 & Note No. 2)

Note 1

In Q2FY26, the company issued 13,98,463 Equity Shares at an issue price of Rs. 357 (including a premium of Rs. 347.00) aggregating to Rs. 49.92 crore.

Note 2

Particulars	Amount as per the Prospectus (Rs. in crore)
Total Proceeds Received from Right Issue	49.92
Less: Issue Related to Expenses	0.47*
Net Proceeds Available for Utilization	49.45**

Note: The company has received Rs. 49.92 crore from the rights issue during Q2FY2026. Out of these Rs. 1.08 crore were utilized towards issue related expenses. However, since the allocation in prospectus towards issue related expenses was estimated at Rs. 0.47 crore, the balance of issue related expenses i.e. Rs. 0.61 crore were utilized towards the object of General Corporate Purposes.

*Issue related expenses as per prospectus

**Infomerics Ratings shall be monitoring the Net Proceeds

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of Board of Directors
Whether all the utilization is as per disclosure in Offer Document?	Yes	Bank Statement, CA Certificate*, Invoices, Prospectus	Refer Note 1	No Comments

Whether Shareholder approval is obtained in case of material deviations from expenditures disclosed in Offer Document?	Not Applicable	NA	No Comments	No Comments
Whether means of finance for disclosed objects of the Issue has changed?	There is no change in means of finance	NA	No Comments	No Comments
Any major deviation observed over the earlier monitoring agency reports?	Not Applicable	Not Applicable	Not Applicable	No Comments
Whether all Government / Statutory approvals related to the object(s) obtained?	Yes	Principal approval from NSE & BSE	No Comments	No Comments
Whether all arrangements pertaining to technical assistance/collaboration in operation?	Not Applicable	Not applicable	Not Applicable	No Comments
Any favourable events improving object(s) viability	There are no events affecting the viability of the objects of the issue.	Not applicable	Nil	No Comments

Any unfavourable events affecting object(s) viability	There are no events affecting the viability of the objects of the issue.	Not applicable	Nil	No Comments
Any other relevant information that may materially affect the decision making of the investors	There is no other relevant information that may affect the decision making of the investor.	Not applicable	Nil	No Comments

* The above details are verified by statutory auditors, M/s. C. Sharat & Associates, Chartered Accountants (Membership Number: 127551) vide its CA certificate dated 12 November 2025. Auditor's remark: No deviation / variation in use of funds raised.

Note 1: The company made payments to various vendors towards the capex of its Greenfield Project at Pen, Maharashtra. Total utilization towards the project during Q2FY2026 out of the issue proceeds amounted to Rs. 18.30 crore. Further the company had incurred a total of Rs. 1.08 crore towards issue related expenses. However, since the allocation in prospectus towards issue related expenses was estimated at Rs. 0.47 crore, the balance of issue related expenses i.e. Rs. 0.61 crore were utilized towards the object of General Corporate Purposes.

^ Material Deviation would mean

- a) deviation in the objects or purposes for which the funds have been raised
- b) deviation in the amount of funds actually utilised by more than 10% of the amount projected in the offer document

4) **Details of object(s) to be monitored:**

(i) **Cost of object(s)-**

Sl. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of Monitoring Agency	Comments of Board of Directors		
						Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1	Funding Capital Expenditure for Greenfield Project at Pen, Maharashtra, India	CA Certificate* and Final Prospectus**	47.00	Not Applicable	No comments	No Comments	No Comments	No Comments
2	General Corporate Purposes	CA Certificate* and Final Prospectus**	2.45	Not Applicable	No comments	No Comments	No Comments	No Comments

	TOTAL		49.45			No Comments	No Comments	No Comments
--	--------------	--	--------------	--	--	----------------	-------------	----------------

*CA Certificate dated 12 November 2025, issued by M/s. C. Sharat & Associates, Chartered Accountant, Statutory Auditors of the Company.

**Sourced from final prospectus dated 12 July 2025, Page No. 47

(ii) Progress in the object(s)-

Sl. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount raised till September 30, 2025 (Rs. crore)	Amount utilized			Unutilised amount in Rs. crore	Comments of Monitoring Agency	Comments of Board of Directors	
					As at Beginning of the quarter	During the quarter	At the end of the quarter			Reason of idle funds	Proposed Course of Action
1	Funding Capital Expenditure for Greenfield	CA Certificate*, Bank	47.00	47.00	-	18.30	18.30	28.70	No Comments	No Comments	No Comments

	Project at Pen, Maharashtra, India	Statements, and Prospectus									
2	General Corporate Purposes	CA Certificate*, Bank Statements, and Prospectus	2.45	2.45	-	0.61	0.61	1.84	Refer Note 1 below	No Comments	No Comments
TOTAL			49.45	49.45	-	18.91	18.91	30.54			

*Certificate issued by company's statutory auditors, i.e. M/s. C. Sharat & Associates, Chartered Accountants dated 12 November 2025

**Sourced from prospectus issued by the company dated July 12, 2025

Note 1: The company had incurred a total of Rs. 1.08 crore towards issue related expenses. However, since the allocation in prospectus towards issue related expenses was estimated at Rs. 0.47 crore, the balance of issue related expenses i.e. Rs. 0.61 crore were utilized towards the object of General Corporate Purposes.

#Brief description of Object(s):

S.no	Name of the object(s)	Brief description of the object(s)
1	Funding Capital Expenditure for Greenfield Project at Pen, Maharashtra, India	Company have witnessed a consistent increase in demand for products across domestic and international markets. Navi Mumbai facility is presently operating at or near full capacity. To cater to this growing demand and enhance operational scalability, company propose establishing a new Greenfield manufacturing facility at Survey. No. 24/1 to 46, 48 to 56 & 58 to 71, Village - Maldev, Khopoli Pen Road, Khopoli: 410203, Maharashtra India.
2	General Corporate Purposes	Company intends to deploy the balance Net Proceeds aggregating Rs 2.45 crore towards general corporate purposes, provided that the amount to be utilized for general corporate purposes shall not exceed 25% of the Gross Proceeds. Such utilisation towards general corporate purposes shall be to drive business growth, including, amongst other things, investments for inorganic growth, capital expenditure, funding growth opportunities, including strategic initiatives, meeting working capital requirements, payment of principal, interest on borrowings, and, meeting of exigencies which Company may face in its course of the business and any other purpose as permitted by applicable laws and as approved by our Board or a duly appointed committee thereof, subject to meeting regulatory requirements and obtaining necessary approvals/ consents, as applicable. Management will have flexibility in utilizing the proceeds earmarked for general corporate purposes.

(iii) Deployment of unutilized Issue proceeds-

Sl. no.	Type of instrument where amount invested	Amount invested (in Crores)	Maturity date	Earnings (in Crores)	Return on Investment (ROI %)	Market Value as at the end of quarter
---------	--	-----------------------------	---------------	----------------------	------------------------------	---------------------------------------

1	FDs placed with Kotak Mahindra Bank	30.52	29-08-2026	-	6.25%	30.52
	Balance in Kotak Mahindra Bank Monitoring Account	0.02	NA	NA	NA	0.02
	Total	30.54	NA	NA	NA	30.54

(iv) Delay in implementation of the object(s)-

Object(s) Name	Completion Date		Delay (No. of days/ months)	Comments of Board of Directors	
	As per Offer Document	Actual *		Reason of delay	Proposed Course of Action
Funding Capital Expenditure for Greenfield Project at Pen, Maharashtra, India	Till FY 2026	Ongoing	No delay	No Comments	No Comments

General Purposes	Corporate	Till FY 2026	Ongoing	No delay	No Comments	No Comments
------------------	-----------	--------------	---------	----------	-------------	-------------

v) Details of utilisation of Proceeds stated as General Corporate Purpose (GCP) amount in the offer document: Not Applicable

S.No	Item Head	Amount in Rs. Crore	Source of Information/Certifications Considered by the Monitoring agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	Issue related expenses	0.61	Invoices, Ledgers, Bank Statements, Final Prospectus	Refer Note below	No Comments

Note: The company had incurred a total of Rs. 1.08 crore towards issue related expenses. However, since the allocation in prospectus towards issue related expenses was estimated at Rs. 0.47 crore, the balance of issue related expenses i.e. Rs. 0.61 crore were utilized towards the object of General Corporate Purposes.

DISCLAIMERS:

- This Report is prepared by Infomerics Valuation and Rating Limited (hereinafter referred to as "Monitoring Agency" / "MA" / "IVRL"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors/independent chartered accountant appointed by the Issuer believed by it to be accurate and reliable.
- Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors, lawyers, chartered engineers or other experts, and relies on in its reports
- The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.
- The MA report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as MA providing or intending to provide any services in jurisdictions outside India, where it does not have the necessary licenses and/or registration to carry out its business activities referred to above.
- Access or use of this report does not create a client relationship between MA and the user.
- MA is not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing this report, MA has not taken into consideration the objectives or particular needs of any particular user.
- It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains.

- The report comprises professional opinion of MA as of the date they are expressed, based on the information received from the issuer and other sources considered reliable by MA. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. The report does not constitute statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions.
- Neither MA nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents guarantee the accuracy, completeness or adequacy of the report, and shall not have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. MA and each aforesaid party disclaim any and all express or implied warranties, including but not limited to any warranties of merchantability, suitability or fitness for a particular purpose or use or use. In no event shall MA or any aforesaid party be liable to any user for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.
- MA has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with the preparation of this report. MA has in place a code of conduct and policies for managing conflict of interest.
- Unless required under any applicable law, this report should not be reproduced or redistributed to any other person or in any form without prior written consent from MA.
- By accepting a copy of this Report, the recipient accepts the terms of this Disclaimer, which forms an integral part of this Report.